Omeros Corporation announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. These patients were part of the “second surge” of COVID-19 in Italy. Narsoplimab is the company’s lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement. The patients were treated under compassionate use at ASST Papa Giovanni XXIII Hospital between October 2020 and April 2021. Highlights of the study are as follows: Baseline characteristics of the 10 study patients: Median age: 65 years (range 41 to 79 years); 90% were men; All had comorbidities/risk factors for poor outcome (i.e., diabetes, cardiovascular disease/hypertension, overweight/obese, dyslipidemia); Acute respiratory distress syndrome (ARDS) severity (by Berlin criteria) at time of intubation or ICU admission: 80% severe, 20% moderate; All had failed other therapies (steroids).